PurposeThis study aimed to investigate whether serum neuron-specific enolase (NSE) was expressed in acute encephalitis syndrome (AES) that causes neuronal damage in children.MethodsThis prospective observational study was conducted in the pediatric neurology ward of Soetomo Hospital. Cases of AES with ages ranging from 1 month to 12 years were included. Cases that were categorized as simple and complex febrile seizures constituted the non-AES group. Blood was collected for the measurement of NSE within 24 hours of hemodynamic stabilization. The median NSE values of both groups were compared by using the Mann-Whitney U test. All statistical analyses were performed with SPSS version 12 for Windows.ResultsIn the study period, 30 patients were enrolled. Glasgow Coma Scale mostly decreased in the AES group by about 40% in the level ≤8. All patients in the AES group suffered from status epilepticus and 46.67% of them had body temperature >40℃. Most of the cases in the AES group had longer duration of stay in the hospital. The median serum NSE level in the AES group was 157.86 ng/mL, and this value was significantly higher than that of the non-AES group (10.96 ng/mL; P<0.05).ConclusionAES cases showed higher levels of serum NSE. These results indicate that serum NSE is a good indicator of neuronal brain injury.
Epilepsy is a disruption of brain function that is characterized by abnormal depolarization of neurons. One signs of epilepsy is seizures, which caused by brain injury. Epilepsy can cause morbidity and mortality, thus, many drugs are used to treat epilepsy. But these drugs have negative health effects. This research was using semax peptide as alternative therapy, because it is a neuropeptide that directly acts on the central nervous system and free from hormonal activity, therefore it will not cause negative health effects. Moreover, semax peptide is an antioxidant and can synthesize some proteins in brain. The potency of semax peptide therapy on epilepsy rats can be analyzed by MDA level and proteins profiles on the brain. The epilepsy rats were prepared by using LiCl and pilocarpine induction. Then rats were treated with 50 µg/kg body weight of semax peptide. Analysis of MDA level was measured using TBA test while protein profiles were determined using SDS-PAGE method. The result showed that semax peptide reduced MDA levels up to 40.46% and synthesize 3 kinds of proteins that were not synthesized on epilepsy rats. Those proteins have molecular weights of 93.54 kDa, 66.76 kDa, and 59.66 kDa. In conclusion, 50 µg/kg body weight dose of semax peptide can be used for the treatment of epilepsy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.